

Vemlidy® (tenofovir alafenamide) – New indication

- On March 28, 2024, <u>Gilead announced</u> the FDA approval of <u>Vemlidy (tenofovir alafenamide)</u>, for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease.
 - Vemlidy was previously approved for this indication in adults and pediatric patients 12 years of age and older.
- The approval of Vemlidy for the expanded indication was based on a randomized, double-blind, placebo-controlled study (Trial 1092; Cohort 2) of 18 treatment naïve and treatment-experienced patients between the ages of 6 to less than 12 years weighing at least 25 kg. Patients were randomized to receive Vemlidy or placebo.
 - At week 96, HBV DNA < 20 IU/mL was achieved in 50% of patients with Vemlidy vs. 33% with placebo.
 - No clinically meaningful differences in pharmacokinetics or safety were observed in comparison to those observed in adults.
- Vemlidy carries a boxed warning for discontinuation of anti-hepatitis B therapy may result in severe acute exacerbations of hepatitis B.
- The recommended dosage of Vemlidy in adults and pediatric patients 6 years of age and older and weighing at least 25 kg is one 25 mg tablet taken orally once daily with food.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.